The overprescription of antidepressants and its impact on the elderly in Australia

Alduhishy, Muath

doi:10.1590/2237-6089-2016-0077

Cited by 17 publications

(12 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increase in the use of antidepressants from 2014 to 2019 was also observed in other countries, members of the Organization for Economic Co-operation and Development, but at a lower rate: Canada (39%), Chile (20%), Estonia (49%), Iceland (27%), Israel Frontiers in Pharmacology frontiersin.org (28%), Latvia (60%), Portugal (35%), and Sweden (17%), among others (Organization for Economic Co-operation and Development, 2020). The use of antidepressants has been increasing in the last decades worldwide, suggesting that affective disorders are getting more common or more diagnosed or even drug companies could be increasing efforts to promote these drugs (Alduhishy, 2018). The increase of antidepressant use also may reflect improvements of mental health services and implementation of national policies that promote drug affordability, such as the generic drug policy.…”

Section: Discussionmentioning

confidence: 99%

Trends in Brazilian market of antidepressants: A five-year dataset analysis

et al. 2022

View full text Add to dashboard Cite

Introduction: Depression is an emotional disorder associated with morbidities and disabilities worldwide. The growing use of antidepressants is a concern for health managers because there are still unanswered questions on the effectiveness and safety of these medicines. Drug sales have increased in Brazil in recent years, but investigations on antidepressants sales are not available. We aimed to describe the trends in the antidepressant commerce in Brazil in a five-year period.Materials and Methods: We performed an ecological study on antidepressant sales in Brazil, from November 2014 to October 2019, using data from IQVIA™, a data provider of pharmaceutical sales. Antidepressants were coded by the Anatomical Therapeutic Chemical classification system, and sales were presented in defined daily doses (DDDs) and DDDs per 1,000 inhabitants per day (DIDs). The results were expressed in absolute quantities and growth rates.Results: The analyzed dataset contained 23 active substances in 780 products. The total sales of antidepressants increased from 23.3 DIDs in November 2014 to 38.3 DIDs in October 2019 (p = 0.002). Selective serotonin reuptake inhibitors were the most sold category of drugs (+5.7 million DDDs) in the period. ‘Other’ antidepressants presented the largest growth rate (104.7%). Individually, the most sold active substance was escitalopram (+1.8 million DDDs), and vortioxetine had the largest growth rate (336.2%). Tricyclic sales remained unchanged, and monoamine oxidase inhibitors had low and even decreasing sales (−9.5%).Discussion: The total sales of antidepressants increased in Brazil from November 2014 to October 2019. The higher sale volumes of selective serotonin reuptake inhibitors and higher growth rate of ‘other’ antidepressants, with low sale volume of tricyclics and a decrease of monoamine oxidase inhibitors, suggest the replacement of older drugs by newer ones following a global trend. Therapeutic advances and commercial promotion efforts on new products might explain these findings.

show abstract

Section: Discussionmentioning

confidence: 99%

Trends in Brazilian market of antidepressants: A five-year dataset analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Every fifth person in developed countries has been subject to a depressive disorder at some point, and the situation is even worse in third world countries. Depression is the most common type of psychiatric disorders today, making antidepressants some of the most commonly prescribed drugs [2,3]. According to the diagnostic and Statistical Manual of Mental disorders (DSM-5), major depressive disorder (MDD) is diagnosed sustaining the following symptoms for at least two weeks: depressed mood, excessive guilt, anhedonia, suicidal ideation, changes in appetite and sleep, psychomotor retardation, poor concentration, and fatigue.…”

Section: Introductionmentioning

confidence: 99%

Bacterial Metabolites of Human Gut Microbiota Correlating with Depression

Averina

Zorkina

Yunes

et al. 2020

IJMS

View full text Add to dashboard Cite

Depression is a global threat to mental health that affects around 264 million people worldwide. Despite the considerable evolution in our understanding of the pathophysiology of depression, no reliable biomarkers that have contributed to objective diagnoses and clinical therapy currently exist. The discovery of the microbiota-gut-brain axis induced scientists to study the role of gut microbiota (GM) in the pathogenesis of depression. Over the last decade, many of studies were conducted in this field. The productions of metabolites and compounds with neuroactive and immunomodulatory properties among mechanisms such as the mediating effects of the GM on the brain, have been identified. This comprehensive review was focused on low molecular weight compounds implicated in depression as potential products of the GM. The other possible mechanisms of GM involvement in depression were presented, as well as changes in the composition of the microbiota of patients with depression. In conclusion, the therapeutic potential of functional foods and psychobiotics in relieving depression were considered. The described biomarkers associated with GM could potentially enhance the diagnostic criteria for depressive disorders in clinical practice and represent a potential future diagnostic tool based on metagenomic technologies for assessing the development of depressive disorders.

show abstract

“…Um estudo indica que a população brasileira tem a maior prevalência de depressão e ansiedade da América Latina, com taxas de 5,8% e 9,3%, respectivamente 9 . Por outro lado, os transtornos psiquiátricos, especialmente depressão, têm sido sobrediagnosticados em uma escala considerável, levando a uma lista de consequências adversas significativas que afetam principalmente os grupos de indivíduos mais vulneráveis 10 .…”

Section: Introductionunclassified

Descrição do consumo de psicofármacos na atenção primária à saúde de Ribeirão Preto, São Paulo, Brasil

et al. 2021

View full text Add to dashboard Cite

O consumo de psicofármacos é considerado um problema de saúde pública devido ao potencial de dependência e ocorrência de eventos adversos. Nesse contexto, o presente estudo teve como objetivo caracterizar o consumo de psicofármacos dispensados em unidades básicas de saúde de Ribeirão Preto, São Paulo, Brasil. Conduziu-se um estudo ecológico, com consulta à base de dados Hygia de 2008 a 2012. Foram extraídas as variáveis: psicofármaco dispensado, quantidade dispensada no ano, sexo e faixa etária dos pacientes. Para cada psicofármaco foi calculada a dose diária definida por 1.000 habitantes/dia (DDD/1.000PD), a dose diária definida por 1.000 habitantes/dia considerando-se 75% da população (DDD75%/1.000PD) que retiraram medicamento pelo Sistema Único de Saúde (SUS) e a dose diária prescrita (DDP). Comparou-se a taxa de crescimento populacional com a de crescimento do consumo dos medicamentos. Foram identificados 1.577.241 pacientes que retiraram medicamentos no período avaliado, dos quais 287.373 (18,2%) utilizaram pelo menos um sujeito a controle especial. Houve aumento do consumo total dos psicofármacos (DDD/1.000PD), porém, após a comparação com a taxa de crescimento populacional, apenas a da sertralina (p = 0,021), risperidona (p = 0,034) e do clonazepam (p = 0,043) foram superiores. As DDP de sete fármacos estavam maiores que a DDD da Organização Mundial da Saúde (OMS). As discrepâncias entre DDD e DDP podem ser úteis como estratégia para triar pacientes elegíveis ao cuidado farmacêutico, pois podem contribuir na prevenção de morbimortalidade relacionada ao uso de medicamentos.

show abstract

The overprescription of antidepressants and its impact on the elderly in Australia

Cited by 17 publications

References 13 publications

Trends in Brazilian market of antidepressants: A five-year dataset analysis

Trends in Brazilian market of antidepressants: A five-year dataset analysis

Bacterial Metabolites of Human Gut Microbiota Correlating with Depression

Descrição do consumo de psicofármacos na atenção primária à saúde de Ribeirão Preto, São Paulo, Brasil

Contact Info

Product

Resources

About